The global pneumococcal vaccines market is projected to have an average-paced CAGR of 4.1% during the forecast period. The current valuation of the market is USD 8.9 Billion in 2023. The market value of the pneumococcal vaccines market is anticipated to surpass a market valuation of USD 13.3 Billion by 2033.
A historical market valuation of USD 8.5 Billion has been recorded by the analysts of Future Market Insights for the concerned market during the base year.
Growth is supported by:
| Report Attribute | Details |
|---|---|
| Pneumococcal Vaccines Market Value (2023) | USD 8.9 Billion |
| Pneumococcal Vaccines Market Anticipated Value (2033) | USD 13.3 Billion |
| Pneumococcal Vaccines Projected Growth Rate (2023 to 2033) | 4.1% |
Although the market is estimated to have favorable growth through the forecast period, it is identified that certain factors prevailing in the market are likely to curb the demand for pneumococcal vaccines in the forthcoming years.
It is witnessed that the manufacturing or production process of pneumococcal vaccines requires a longer timeline, which acts as a key restraining element in the market expansion.
Additionally, there is a very high cost associated with the development of pneumococcal vaccines. Therefore, it is expected that the aforementioned factors are likely to hinder the propulsion of industry through the forecast period.
The industry players are diversifying their product portfolios with the launch of protein-based vaccines. The introduction of protein-based vaccines is creating several growth opportunities in the market to further expand and upscale the prominence of pneumococcal vaccines.
Protein-based vaccines have inexpensive production procedures that further aid the market’s prominence. Additionally, these products have logistical and protocol advantages, along with the inclusion of stability at a broad range of temperatures.
These vaccines are identified to narrow the immunization gaps that prevail among the middle-class and abundant populace across developing economies. Therefore, it is estimated that the pneumococcal vaccines market is likely to accrue significant shares through the forecast period.
It is identified that the pneumococcal vaccines market is witnessing an unprecedented surge in the recent few years. There has been an approximate rise of USD 0.4 Billion from the base year to the current.
This growth in market valuation can be highly attributed to the rising number of young children under 2 to 5 years possessing a high risk of pneumococcal diseases.
The rising geriatric population has also made a significant contribution to the industry growth of pneumococcal vaccines. Severe complications and contagiousness of diseases in old adults have fostered the growth of the pneumococcal vaccines market during the period 2018 to 2022.
The market advanced at a moderate pace of 3.2% CAGR and accounted for a market value of USD 8.5 Billion in the base year. It is identified that the rise in the number of diabetes patients, smokers, heavy drinkers, and individuals having chronic health conditions, who are vulnerable to ailments and infections owing to their weak immune systems is estimated to further fuel demand through the foreseen years.
Additionally, a key factor making a significant contribution to the market growth is the introduction of the Pneumococcal Conjugate Vaccine (PCV) by government agencies across emerging countries in infant routine immunization. This factor is expected to further trail growth through the projection period.
| Historical CAGR (2018 to 2022) | 3.2% |
|---|---|
| Market Value in 2022 | USD 8.5 Billion |
| Forecast CAGR (2023 to 2033) | 4.1% |
|---|---|
| Market Value in 2023 | USD 8.9 Million |
Prevenar-13 - By Product Type
It is identified that the Prevenar-13 segment by product type category is likely to trail at a significant rate through the forecast period. In the base year, this segment was advancing forward at a CAGR of 3.2% and is likely to hold dominant shares in the pneumococcal vaccines market through 2033.
This segment is projected to account for a revenue share of USD 9,500 Millionin 2023. The growing prominence of Prevenar 13 can be attributed to the inclusion of thirteen pneumococcus and serotypes. The hospital sector is giving this vaccine to patients due to the presence of serotypes 6A and 19A.
The Centers for Disease Control and Prevention (CDC) has also made recommendations for Prevenar-13 for adults, who are above the age of 65 years. Therefore, this segment is likely to accrue significant shares of the market through 2033.
Public Authorities - By Distribution Channel
After an in-depth analysis of the market, it is witnessed that the public authorities segment by distribution channel category is likely to hold dominant shares in the pneumococcal vaccines market. In 2022, this segment trailed at a CAGR of 6.8% and is likely to move forward at a notable pace, registering a CAGR of 5% during the period 2023 to 2033.
Public health agencies and community clinics are accounting for the largest market share owing to the large number of vaccine purchases made by organizations such as GAVI, WHO, UNICEF, and others. These organizations make bulk purchases of pneumonia vaccines and distribute them across diver geographies for social causes.
The hospital segment is also estimated to have grown at a significant rate and is projected to surpass a market valuation of USD 12,400 Million by the end of 2023.
| Region | North America |
|---|---|
| Country | United States of America |
| CAGR (2023 to 2033) | 1.8% |
| Region | Europe |
|---|---|
| Country | United Kingdom |
| CAGR (2023 to 2033) | 2.5% |
| Region | Europe |
|---|---|
| Country | Germany |
| CAGR (2023 to 2033) | 2.9% |
| Region | Asia Pacific |
|---|---|
| Country | China |
| CAGR (2023 to 2033) | 9.0% |
| Region | Asia Pacific |
|---|---|
| Country | India |
| CAGR (2023 to 2033) | 9.2% |
| Country | United States of America |
|---|---|
| Statistics | The USA is estimated to hold the highest share of the pneumococcal vaccines market through the projection period. The pneumococcal vaccines industry in the USA is advancing at a CAGR of 1.8%. the market is estimated to surpass a valuation of USD 4.9 Billion by the end of 2033. Approximate Growth in Market Value: USD 825.6 Million Historical CAGR: 0.4% |
| Growth Propellants | A well-established healthcare infrastructure across the North American region serving a large number of patients is estimated to foster the growth of the pneumococcal market in the upcoming years. It is identified that the 5-7% mortality rate in the USA is due to pneumococcal diseases. The rapid growth in the geriatric population is also a key factor fueling the market expansion of pneumococcal vaccines. |
| Country | Germany |
|---|---|
| Statistics | Germany is likely to hold a significant share of the pneumococcal vaccines market in the European region. The pneumococcal vaccines industry in the UK is advancing at a CAGR of 2.9%. The market is estimated to surpass a valuation of USD 191.9 Million by the end of 2033. Approximate Growth in Market Value: USD 47.2 Million Historical CAGR: 2.1% |
| Growth Propellants | The high prevalence and invasion of pneumonia across the people of Europe which accounted for approximately 15.08% of 1,00,000 people is a key cause fueling the market size of pneumococcal vaccines in Germany. A growing number of research and development activities and clinical trials aided by government advances in the country is reshaping the industry landscape in 2023. |
| Country | China |
|---|---|
| Statistics | The pneumococcal vaccines market in China is estimated to move forward at a substantial rate, slating a CAGR of 9.0% through the forecast period. The market is estimated to surpass a valuation of USD 2.9 Billion by the end of 2033. Approximate Growth in Market Value: USD 1.7 Billion Historical CAGR: 35.3% |
| Growth Propellants | The medical healthcare sector across China is witnessing a rise in investment from government authorities. Medical institutes across China are heavily using pneumococcal vaccines for treating diseases like meningitis, blood-stream infection, and more. Therefore, it is estimated to emerge as one of the most significant and remunerative markets in the pneumococcal vaccine landscape. |
The new entrants in the pneumococcal vaccines market are leveraging advancements in technology to launch new products and gain a competitive advantage. These firms are continually investing in research and development activities to keep themselves in tandem with the changing consumer preferences and end-use industry demands.
Efforts are being made to strengthen their foothold in the market and aid the further progression of the pneumococcal vaccines market.
Affinivax - This firm is a clinical-stage biopharmaceutical organization, who are having a next-generation technology platform for vaccines known as the multiple antigen presentation systems. This firm is likely to penetrate the market and be in tandem with the demand from the hospital sector through the forecast period.
GPN Vaccine - This is an Australian start-up firm that is offering vaccines for pneumonia. The startup sterilizes its proprietary, engineered, and avirulent strain of S. pneumonia with gamma rays to produce Gamma-PNTM, a whole-cell vaccine. The vaccine induces broad-spectrum immunity against the antigens of the pneumococcus bacterium and is effective against different pathogenic pneumococcal strains.
The pneumococcal vaccines market is highly fragmented and the key manufacturers are deploying several organic and inorganic growth strategies to compete with the existing players in the market.
The biggies are heavily investing in research and development activities to leverage advancements to the attributes of pneumococcal vaccines. They are making attempts for treating the chronic diseases prevailing amongst the geriatric population and others in an effective manner.
Activirosomes is developing vaccines for viral infections. The company is leveraging active virosome technology for the generation of non-replicating derivates of measles and some other comprehensive viruses. The virosome-based vaccines are carrying only the viral genes that are necessary for eliciting an immune response.
Recent Developments
Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Product Type, 2017 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Distribution Channels, 2017 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Sector, 2017 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2017 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Product Type, 2017 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Distribution Channels, 2017 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Sector, 2017 to 2033
Table 9: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Product Type, 2017 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Distribution Channels, 2017 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by Sector, 2017 to 2033
Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2033
Table 14: Asia Pacific Market Value (US$ Million) Forecast by Product Type, 2017 to 2033
Table 15: Asia Pacific Market Value (US$ Million) Forecast by Distribution Channels, 2017 to 2033
Table 16: Asia Pacific Market Value (US$ Million) Forecast by Sector, 2017 to 2033
Table 17: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2033
Table 18: Latin America Market Value (US$ Million) Forecast by Product Type, 2017 to 2033
Table 19: Latin America Market Value (US$ Million) Forecast by Distribution Channels, 2017 to 2033
Table 20: Latin America Market Value (US$ Million) Forecast by Sector, 2017 to 2033
Table 21: Rest of the World Market Value (US$ Million) Forecast by Country, 2017 to 2033
Table 22: Rest of the World Market Value (US$ Million) Forecast by Product Type, 2017 to 2033
Table 23: Rest of the World Market Value (US$ Million) Forecast by Distribution Channels, 2017 to 2033
Table 24: Rest of the World Market Value (US$ Million) Forecast by Sector, 2017 to 2033
Figure 1: Global Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Distribution Channels, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Sector, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2017 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Product Type, 2017 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Distribution Channels, 2017 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Distribution Channels, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Distribution Channels, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by Sector, 2017 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Sector, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Sector, 2023 to 2033
Figure 17: Global Market Attractiveness by Product Type, 2023 to 2033
Figure 18: Global Market Attractiveness by Distribution Channels, 2023 to 2033
Figure 19: Global Market Attractiveness by Sector, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Distribution Channels, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by Sector, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2017 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Product Type, 2017 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Distribution Channels, 2017 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Distribution Channels, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Distribution Channels, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Sector, 2017 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Sector, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Sector, 2023 to 2033
Figure 37: North America Market Attractiveness by Product Type, 2023 to 2033
Figure 38: North America Market Attractiveness by Distribution Channels, 2023 to 2033
Figure 39: North America Market Attractiveness by Sector, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Europe Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 42: Europe Market Value (US$ Million) by Distribution Channels, 2023 to 2033
Figure 43: Europe Market Value (US$ Million) by Sector, 2023 to 2033
Figure 44: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2033
Figure 46: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) Analysis by Product Type, 2017 to 2033
Figure 49: Europe Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 50: Europe Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 51: Europe Market Value (US$ Million) Analysis by Distribution Channels, 2017 to 2033
Figure 52: Europe Market Value Share (%) and BPS Analysis by Distribution Channels, 2023 to 2033
Figure 53: Europe Market Y-o-Y Growth (%) Projections by Distribution Channels, 2023 to 2033
Figure 54: Europe Market Value (US$ Million) Analysis by Sector, 2017 to 2033
Figure 55: Europe Market Value Share (%) and BPS Analysis by Sector, 2023 to 2033
Figure 56: Europe Market Y-o-Y Growth (%) Projections by Sector, 2023 to 2033
Figure 57: Europe Market Attractiveness by Product Type, 2023 to 2033
Figure 58: Europe Market Attractiveness by Distribution Channels, 2023 to 2033
Figure 59: Europe Market Attractiveness by Sector, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: Asia Pacific Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 62: Asia Pacific Market Value (US$ Million) by Distribution Channels, 2023 to 2033
Figure 63: Asia Pacific Market Value (US$ Million) by Sector, 2023 to 2033
Figure 64: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Asia Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2033
Figure 66: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Asia Pacific Market Value (US$ Million) Analysis by Product Type, 2017 to 2033
Figure 69: Asia Pacific Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 70: Asia Pacific Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 71: Asia Pacific Market Value (US$ Million) Analysis by Distribution Channels, 2017 to 2033
Figure 72: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channels, 2023 to 2033
Figure 73: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channels, 2023 to 2033
Figure 74: Asia Pacific Market Value (US$ Million) Analysis by Sector, 2017 to 2033
Figure 75: Asia Pacific Market Value Share (%) and BPS Analysis by Sector, 2023 to 2033
Figure 76: Asia Pacific Market Y-o-Y Growth (%) Projections by Sector, 2023 to 2033
Figure 77: Asia Pacific Market Attractiveness by Product Type, 2023 to 2033
Figure 78: Asia Pacific Market Attractiveness by Distribution Channels, 2023 to 2033
Figure 79: Asia Pacific Market Attractiveness by Sector, 2023 to 2033
Figure 80: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 81: Latin America Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 82: Latin America Market Value (US$ Million) by Distribution Channels, 2023 to 2033
Figure 83: Latin America Market Value (US$ Million) by Sector, 2023 to 2033
Figure 84: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2033
Figure 86: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Latin America Market Value (US$ Million) Analysis by Product Type, 2017 to 2033
Figure 89: Latin America Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 90: Latin America Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 91: Latin America Market Value (US$ Million) Analysis by Distribution Channels, 2017 to 2033
Figure 92: Latin America Market Value Share (%) and BPS Analysis by Distribution Channels, 2023 to 2033
Figure 93: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channels, 2023 to 2033
Figure 94: Latin America Market Value (US$ Million) Analysis by Sector, 2017 to 2033
Figure 95: Latin America Market Value Share (%) and BPS Analysis by Sector, 2023 to 2033
Figure 96: Latin America Market Y-o-Y Growth (%) Projections by Sector, 2023 to 2033
Figure 97: Latin America Market Attractiveness by Product Type, 2023 to 2033
Figure 98: Latin America Market Attractiveness by Distribution Channels, 2023 to 2033
Figure 99: Latin America Market Attractiveness by Sector, 2023 to 2033
Figure 100: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 101: Rest of the World Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 102: Rest of the World Market Value (US$ Million) by Distribution Channels, 2023 to 2033
Figure 103: Rest of the World Market Value (US$ Million) by Sector, 2023 to 2033
Figure 104: Rest of the World Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: Rest of the World Market Value (US$ Million) Analysis by Country, 2017 to 2033
Figure 106: Rest of the World Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: Rest of the World Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: Rest of the World Market Value (US$ Million) Analysis by Product Type, 2017 to 2033
Figure 109: Rest of the World Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 110: Rest of the World Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 111: Rest of the World Market Value (US$ Million) Analysis by Distribution Channels, 2017 to 2033
Figure 112: Rest of the World Market Value Share (%) and BPS Analysis by Distribution Channels, 2023 to 2033
Figure 113: Rest of the World Market Y-o-Y Growth (%) Projections by Distribution Channels, 2023 to 2033
Figure 114: Rest of the World Market Value (US$ Million) Analysis by Sector, 2017 to 2033
Figure 115: Rest of the World Market Value Share (%) and BPS Analysis by Sector, 2023 to 2033
Figure 116: Rest of the World Market Y-o-Y Growth (%) Projections by Sector, 2023 to 2033
Figure 117: Rest of the World Market Attractiveness by Product Type, 2023 to 2033
Figure 118: Rest of the World Market Attractiveness by Distribution Channels, 2023 to 2033
Figure 119: Rest of the World Market Attractiveness by Sector, 2023 to 2033
Figure 120: Rest of the World Market Attractiveness by Country, 2023 to 2033
The growth outlook for the market is predicted to advance at a CAGR of 4.1% from 2023 to 2033.
The North American region is anticipated to lead the market during the forecast period.
The market valuation of the market stands at USD 8.9 Billion in 2023.
The market is likely to hold a valuation of USD 13.3 Billion by 2033.
The healthcare industry sector is the key driver in the market.
Explore Therapy Area Insights
Pneumococcal Vaccines Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
